SMMT Summit Therapeutics Inc.

AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical deadlines in 2026 will determine whether Wall Street or the pharma giant read ivonescimab correctly.

Summit Therapeutics stock jumped Tuesday after AstraZeneca made a $2 billion investment in the smaller biotech.

AstraZeneca stock sinks as management announces $2 billion investment in Summit Therapeutics. But should you buy the dip in AZN shares today? Let’s find out!

AstraZeneca's (AZN) $2 billion investment in Summit Therapeutics (SMMT) is a "win-win" and potential

A preferred-equity investment secures collaboration access without the cost and integration risk of an acquisition.

The companies will start by testing ivonescimab with an AstraZeneca ADC in gastrointestinal cancers

The deal would give AstraZeneca exposure to a promising cancer treatment without acquiring the company outright.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2% and the actively trad

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock

The equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but doesn’t hand the pharmaceutical company any ownership rights.

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical company, has won positive responses from UBS and Jefferies after investing $2 billion in Summit Therapeutics and agreeing a cancer drug collaboration. UBS said the investment gives AstraZeneca exposure to the programmed...

Summit Therapeutics (SMMT) is back in focus after presenting new Phase III ivonescimab data in non small cell lung cancer, including updated overall survival and safety results, at the IASLC 2026 World Conference on Lung Cancer. Those fresh ivonescimab updates land after a sharp run, with Summit Therapeutics’ 30 day share price return of 30.34% and 90 day gain of 23.67% contrasting with a slightly negative year to date move. At the same time, the 3 year total shareholder return above 8x hints...

Healthcare stocks advanced late Monday afternoon, with the NYSE Healthcare Index up 1.5% and the Sta

As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings that impressed Wall Street.

Summit Therapeutics (NASDAQ:SMMT) shares rose 5. 8% in premarket trading on Wednesday after Jefferies upgraded the biopharmaceutical company to Buy from Hold and increased its price target to $25 from $15.

Uber initiated, Thermo Fisher upgraded: Wall Street's top analyst calls

Uber initiated, Thermo Fisher upgraded: Wall Street's top analyst calls

Summit Therapeutics Inc. (NASDAQ:SMMT) said partner Akeso reported a statistically significant overall survival benefit for ivonescimab monotherapy over pembrolizumab in a prespecified interim analysis of Phase 3 HARMONi-2. The randomized, double-blind study enrolled 398 patients at 55 hospitals in China with previously untreated, PD-L1-positive advanced non-small cell lung cancer without sensitizing EGFR mutations or ALK […]

Summit Therapeutics (NASDAQ:SMMT) has seen its share price surge by 28.19 percent week-on-week, primarily driven by the positive results of an ongoing clinical trial for its bispecific antibody, ivonescimab. In an updated report during the week, the listed biopharmaceutical firm said that its China-based partner, Akeso Inc., saw positive overall survival results from the randomized […]

Summit Therapeutics stock jumps 17% after ivonescimab showed a significant overall survival benefit over Keytruda in a China phase III lung cancer study.

Summit Therapeutics stock rocketed Thursday after its experimental cancer drug outperformed Merck's blockbuster, Keytruda.

Summit says its ivonescimab is keeping lung-cancer patients alive longer than Keytruda does. The stock is up.

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Summit Therapeutics (SMMT) drew fresh attention after partner Akeso reported positive topline results from the Phase III HARMONi-GI1 trial of ivonescimab plus chemotherapy in advanced biliary tract cancer, highlighting another late stage data point around the drug. The HARMONi-GI1 update arrived alongside a series of recent ivonescimab milestones for Summit Therapeutics, and traders reacted quickly. The 1-day share price return was 6.51%, and the 7-day and 30-day share price returns were...

Summit Therapeutics (NasdaqGM:SMMT) reported that Phase III HARMONi trial results for ivonescimab in EGFR-mutated NSCLC have been published in The Lancet Oncology. The pivotal data show significant clinical benefit for patients in the HARMONi study, according to the published results. The company highlighted that ivonescimab for EGFR-mutated NSCLC is currently under ongoing FDA regulatory review. The growing flow of late stage oncology and immunotherapy data makes it worth looking at...

Summit Therapeutics reported that partner Akeso recently delivered positive topline Phase III HARMONi-GI1 data from China, where ivonescimab plus chemotherapy achieved statistically significant and clinically meaningful overall survival, progression-free survival, and response rate benefits over durvalumab plus chemotherapy in first-line advanced biliary tract cancer. This adds a second late-stage success for ivonescimab alongside the previously published HARMONi non-small cell lung cancer...

Akeso reported positive late-stage data for Ivonescimab, a drug that Summit Therapeutics holds the rights to develop and sell outside China.

Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index falling 1.1% and the

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1%, and the actively t

(Updates with economic data, recent oil price changes, world markets' overview, and corporate stock

Summit Therapeutics Inc. (NASDAQ:SMMT) shares climbed 7.

Ivonescimab is currently in global clinical trials for various solid tumour indications, while being under US regulatory review for NSCLC.

Summit Therapeutics (NASDAQ:SMMT) shares gained 1. 1% in pre-market trading after Bernstein SocGen upgraded the biotechnology company to Market Perform from Underperform and raised its price target to $11.

Could these 2 stocks outperform most GLP-1-focused companies over the medium term?

On July 22, Arcus Biosciences, Inc. (NYSE:RCUS) and Summit Therapeutics Inc. (NASDAQ:SMMT) announced a major clinical trial collaboration to combine Arcus’s casdatifan (an investigational HIF-2α inhibitor) with Summit’s ivonescimab (an investigational PD-1/VEGF bispecific antibody). The study aims to evaluate the safety and efficacy of this combination in clear cell renal cell carcinoma (ccRCC), including first-line […]

Summit Therapeutics Inc. on Wednesday shared updated overall survival (OS) data from its Phase 3 HARMONi study, evaluating the investigational bispecific antibody ivonescimab for treating specific forms of lung cancer. The study is evaluating ivonescimab combined with chemotherapy compared to...

Summit Therapeutics Inc (SMMT) reports robust financial health and significant progress in clinical trials, despite facing competitive and regulatory challenges.

Summit Therapeutics (SMMT) drew fresh attention after releasing updated overall survival data from its global Phase III HARMONi trial of ivonescimab plus chemotherapy, a material step in its ongoing FDA review. See our latest analysis for Summit Therapeutics. The updated HARMONi data arrives after a volatile period for Summit Therapeutics, with the share price at $14.98, a 7 day share price return of 8.87% but a 90 day share price return that declined 32.16%, and a very large 3 year total...

Summit Therapeutics (NASDAQ:SMMT) executives used the company’s latest earnings call to emphasize updated survival data for ivonescimab, outline the timing of key late-stage trial readouts and detail the company’s cash position as it prepares for a potential U.S. regulatory decision later this year.

Summit Therapeutics stock has delivered a very large 3 year gain, but its recent slide and a low overall value score suggest the current price may not line up neatly with the fundamentals that have investors excited about its oncology pipeline. Over the past 3 years, Summit Therapeutics has returned about 7x. This puts the recent 1 year decline of 47.4% and year to date drop of 15.9% into sharper focus for anyone trying to judge what is already priced in. Updated positive Phase III data for...

Summit Therapeutics recently reported updated overall survival results from its global Phase III HARMONi trial, showing that ivonescimab plus platinum-doublet chemotherapy continued to deliver a positive survival trend and consistent safety profile versus chemotherapy alone in both Asian and western patients with advanced EGFR-mutated non-squamous non-small cell lung cancer. The latest analysis brought western patients’ overall survival hazard ratio down to 0.76, aligning the magnitude of...

Summit said it has already shared the latest safety data with the U.S. Food and Drug Administration.

New survival data supports ivonescimab treatmentSummit Therapeutics Inc. (NASDAQ:SMMT) shares gained 3% on Wednesday after the company released updated overall survival data from its global Phase III HARMONi trial evaluating ivonescimab in combination with chemotherapy for advanced lung cancer.

A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competitor emerged.

SMMT divests investigational antibiotic ridinilazole to Biossil for upfront cash, milestone payments and royalties as it sharpens its focus on oncology.

J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.